TG Therapeutics (TGTX) Receives a Buy from H.C. Wainwright

In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on TG Therapeutics (TGTXResearch Report), with a price target of $20.00. The company’s shares closed last Monday at $7.12.

According to, White is a 5-star analyst with an average return of 20.9% and a 54.8% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and TRACON Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for TG Therapeutics with a $18.50 average price target, representing a 137.8% upside. In a report issued on November 27, B.Riley FBR also initiated coverage with a Buy rating on the stock with a $12.00 price target.

See today’s analyst top recommended stocks >>

Based on TG Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $61.93 million. In comparison, last year the company had a GAAP net loss of $33.95 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib.